|
Zygomycetes
(Mucormycoses)
Read the Chapter
Sliding Table of
Contents on the left of the screen
Tables and
Figures
Table 1:
Risk Factors and Most Common Clinical Presentation of Zygomycosis
Table 2:
Predisposing Conditions and Therapeutic Approaches against Zygomycosis
Figure 1:
Combined Approach in the Treatment of Zygomycosis
Vignettes
Javey G, Zuravleff J.
Sino-Orbital.
van Burik JA, Hare RS, et al.
Posaconazole is effective as salvage therapy in
zygomycosis: a retrospective summary of 91 cases. Clin Infect
Dis 2006;43(10):1376.
Review Article:
Wahba H,
Truong MT,
Lei X,
Kontoyiannis DP,
Marom EM. Reversed Halo Sign in Invasive
Pulmonary Fungal Infections.
Clin Infect Dis.
2008 Jun 1;46(11):1733-7.
Chamilos G, et al.
Delaying Amphotericin B-based Frontline
Therapy
Significantly Increases Mortality Among Patients with Hematologic Malignancy
Who Have Zygomycosis.Kontoyiannis DP.Clin
Infect Dis. 2008 Aug
15;47(4):503-9.
Ojeda-Uribe M, et al.
Lessons from a Case of Oromandibular Mucormycosis
Treated with Surgery and a Combination of Amphotericin B Lipid Formulation
plus Caspofungin. Acta Haematol. 2010 Aug 3;124:98-102.
Sun HY, Singh N.
Mucormycosis: its contemporary face and management
strategies. Lancet Infect Dis 2011;11:301-310.
Authors
Corina E Gonzalez, M.D.,
Thomas J Walsh, M.D., FACP, FCCP
|
www.antimicrobe.org